Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal a mixed sentiment. The company's financial position is stable with cash reserves, but there is no immediate positive catalyst like a new partnership or record high revenue. The focus is on long-term product development and regulatory approvals, with some uncertainties in timelines and pricing details. The Q&A section shows a cautious yet optimistic management outlook but lacks concrete near-term financial guidance. The market reaction is likely to be neutral, as the stock price may not significantly change without immediate impactful news.
Key Financial Performance
Operating Expenses (Q4 2025) $91.9 million, which included $19.4 million in noncash stock-based compensation. Excluding stock-based compensation, operating expenses were $72.5 million.
Operating Expenses (Full Year 2025) $384.6 million, which included $75.6 million in noncash stock-based compensation. Excluding stock-based compensation, operating expenses were $309 million.
Cash and Cash Equivalents (End of 2025) $368 million, including $60.4 million from the exercise of warrants that were set to expire on December 31.
New Debt Facility Secured a new debt facility for up to $550 million with Blue Owl Capital. This includes $100 million immediately available (used to repay prior debt), $100 million available in Q1 2026, $150 million available upon FDA approval of apitegromab, and an option for additional facilities of up to $200 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Apitegromab: Focused on bringing the world's first muscle-targeted therapy to children and adults with SMA. Progress made with FDA and Novo Nordisk for regulatory approval. U.S. launch expected in 2026 after FDA approval. European Medicines Agency decision anticipated mid-2026. Subcutaneous formulation and additional indications like FSHD are under development.
SRK-439: Phase I study ongoing for this innovative myostatin inhibitor. Top-line data expected in the second half of 2026.
U.S. Market: Commercial team is preparing for the launch of apitegromab. Disease education programs and engagement with SMA treatment centers and prescribers are ongoing. Specialty pharmacy and home infusion networks are established.
European Market: Launch readiness activities are progressing, starting with Germany. Compassionate use program initiated, and reimbursement planning is underway.
Manufacturing: FDA reinspection of Catalent Indiana facility is awaited. Progress with a second fill-finish facility to build redundancy in the supply chain. Supplemental BLA for the second facility expected later in 2026.
Financial Position: Ended 2025 with $368 million in cash and cash equivalents. Secured a new debt facility for up to $550 million to support commercial and R&D priorities.
Pipeline Expansion: Advancing anti-myostatin pipeline with apitegromab and SRK-439. New indications like FSHD and subcutaneous formulations are being prioritized.
Global Expansion: Building a 50-country operating platform in Europe and other regions to support commercialization.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
FDA Warning Letter to Catalent Indiana: The FDA issued a warning letter to Catalent Indiana, which could potentially delay the resubmission of the apitegromab BLA and subsequent approval process.
Manufacturing Site Reinspection: The FDA plans to conduct a site reinspection at Catalent Indiana following routine manufacturing activities, which introduces uncertainty in the timeline for apitegromab approval.
Supply Chain Redundancy: The company is working on a second fill-finish facility to build redundancy into its supply chain, but this facility is still undergoing engineering runs and additional manufacturing runs, which could delay supplemental BLA submission.
Regulatory Approval Timelines: The approval timelines for apitegromab in both the U.S. and Europe are contingent on successful inspections and regulatory reviews, which carry inherent risks of delays.
Commercial Launch Readiness: The company is heavily investing in commercial launch preparations, but any delays in regulatory approval could impact the timing and effectiveness of these efforts.
Financial Dependence on Debt Facility: The company has secured a new debt facility for up to $550 million, but this financial strategy introduces risks related to debt repayment and financial sustainability, especially if apitegromab approval or sales are delayed.
Market Competition: The SMA market is growing but remains competitive, with existing SMN-targeted therapies already generating $5 billion in annual sales. This could impact the market penetration of apitegromab.
Unmet Needs in SMA: While apitegromab addresses muscle weakness, 95% of SMA patients continue to experience persistent muscle weakness, which may limit the perceived efficacy of the therapy.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
BLA Resubmission and U.S. Launch: Scholar Rock plans to resubmit the Biologics License Application (BLA) for apitegromab following a successful FDA reinspection of the Catalent Indiana facility. The U.S. launch is expected in 2026 after approval.
European Medicines Agency (EMA) Decision: The company anticipates a decision from the EMA regarding apitegromab in mid-2026, with plans for a European launch starting in Germany in the second half of the year.
Second Fill-Finish Facility: Engineering runs at a second manufacturing facility are underway, with additional runs planned for Q2 2026. A supplemental BLA for this facility is expected to be submitted later in 2026 to ensure supply chain redundancy.
Phase II OPAL Study: Enrollment and dosing are ongoing in the Phase II OPAL study evaluating apitegromab in infants and toddlers with SMA. This study aims to expand the use of apitegromab to younger patients and those treated with Zolgensma.
Phase II FORGE Study for FSHD: A robust, randomized, placebo-controlled Phase II study for apitegromab in facioscapulohumeral muscular dystrophy (FSHD) is expected to begin in mid-2026, targeting 60 patients.
Subcutaneous Formulation of Apitegromab: Scholar Rock plans to engage with U.S. and European regulators later in 2026 to discuss the clinical and regulatory strategy for the subcutaneous formulation of apitegromab.
SRK-439 Myostatin Inhibitor: Top-line data from the Phase I study of SRK-439, a highly innovative myostatin inhibitor, is expected in the second half of 2026.
Commercial Launch Preparations: The U.S. commercial team is actively preparing for the launch of apitegromab, including disease education, patient access programs, and payer engagement. European launch readiness activities are also progressing.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is Novo now ready for reinspection, and what would trigger the resubmission?
A:Novo is ready for reinspection, and the resubmission would be triggered by a successful reinspection. The company is prepared to submit the BLA very quickly after gaining confidence in the reinspection's success.
Q:What happens to timelines if the backup facility becomes the primary filing?
A:The company believes the timing would not be altered significantly. They are prepared to pivot to the backup facility if necessary, but the plan remains to use it as a supplemental BLA.
Q:What was the purpose of the FDA sending a field team, and what are the next procedural steps post-reinspection?
A:The FDA's field team visit indicates high priority and urgency for the apitegromab file. Post-reinspection, the company expects rapid progress, including resubmission and review, following the steady pace observed over the last three months.
Q:What are the expectations for turnaround time following BLA submission to approval?
A:The company is ready to rapidly resubmit the BLA following a successful reinspection. While they cannot comment on exact timing, they point to the FDA's attentiveness and progress over the last three months as evidence of urgency.
Q:What is the strategy for SRK-439, and will it be kept in-house?
A:SRK-439 is a high-potency anti-myostatin antibody with potential in rare neuromuscular diseases. The company plans to keep it as a proprietary asset and will share further development plans after Phase I data later this year.
Q:Can the U.S. launch still happen in 2026 with a Class II submission?
A:The company is confident in their 2026 guidance for BLA resubmission and U.S. launch. They note that even Class II submissions can sometimes be decided before the six-month timeline.
Q:What are the expectations for the label regarding ambulatory and non-ambulatory patients?
A:The company anticipates a broad label based on prior discussions with the FDA, covering both ambulatory and non-ambulatory patients, children 2 years and older, and patients on other SMA therapies. Final details will depend on the FDA.
Q:How will pricing be determined for apitegromab?
A:Pricing will be weight-based and consider the rarity and severity of SMA, the progressive nature of the disease, and the clinical benefits demonstrated in trials. Specific pricing details will be shared at launch.
Q:What commercial analogs are relevant for the launch trajectory, and what is the timeline for subcutaneous apitegromab approval?
A:The company expects robust demand but anticipates initial access speed bumps. For subcutaneous apitegromab, discussions with regulators are planned for later this year to finalize the path forward.
Q:Would switching to the second fill-finish facility derisk the supply chain?
A:Yes, switching to the second facility would derisk the supply chain for both U.S. and EU launches. The company is making rapid progress with the second facility.
Q:What is the status of the EMA review, and has EMA taken any actions in response to FDA findings?
A:The EMA is aware of the FDA findings and is supportive. Progress with the FDA serves the EMA review well, and the company expects the Catalent remediation and reinspection to support the EMA decision near midyear.
Q:Could the FDA request additional safety data, and what functional endpoints will be used in the FSHD Phase II study?
A:The FDA has aligned with the company on the safety database update required for resubmission. The FSHD Phase II study will focus on increasing lean muscle volume and include validated functional outcome measures.
Q:What are the financial expectations for time to profitability?
A:The company expects a typical rare disease revenue trajectory, reaching profitability 2-3 years post-launch, depending on pipeline progress and investment decisions.
Q:Is there precedent for the FDA reviewing a Class II resubmission in less than six months?
A:Yes, there is precedent, such as Regeneron's case in 2023, where a Class II resubmission was approved within 60 days.
Q:What are the enrollment trends for the OPAL study?
A:Enrollment is progressing well, with strong awareness and interest in a muscle-based approach among the SMA community and prescribers.
Q:How does apitegromab address the historical hurdle of functional improvement in FSHD?
A:Apitegromab's potency and selectivity differentiate it from earlier myostatin inhibitors. The Phase II study will include validated functional outcome measures to assess its impact.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or clarity on the following: 1) Specific timelines for FDA review and approval post-resubmission, 2) Exact pricing details for apitegromab, 3) Detailed timelines for subcutaneous apitegromab approval, and 4) Specific financial guidance for profitability.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BLA FDA
Blue Owl
Catalent Indiana
EMA decision
FDA level
FDA request
FSHD muscle
II study
IV
Indiana facility
Phase II
Type meeting
balance sheet
behalf patient
body
capability launch
caregiver
cash
dosing
engagement
era SMA
field
formulation
launch readiness
manufacturing
meeting FDA
objective
preparation
reimbursement
reinspection
run
specialty pharmacy
stock compensation
subcu
therapy child
world muscle
SRRK Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reflects a mixed outlook. Positive revenue growth of 25% and a slight improvement in net loss are offset by increased R&D and G&A expenses. Regulatory hurdles, market conditions, and supply chain risks present uncertainties. The absence of shareholder return discussions and unclear management responses in the Q&A add to the neutral sentiment. The strategic initiatives are promising but hinge on future regulatory approvals and market conditions. Overall, the stock is likely to remain stable in the short term.
Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
SRRK Slides
SRRK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
